Samsung Biologics is a global contract development and manufacturing organisation (CDMO) offering integrated services for the biologics industry.

Samsung Biologics is a leading CDMO, providing end-to-end services for the development, manufacturing, and commercialisation of biologic drugs. Established as part of the Samsung Group, the company integrates state-of-the-art technologies and extensive expertise to support clients in the biopharmaceutical sector. With a commitment to delivering high-quality therapeutics, Samsung Biologics’ capabilities span from cell line development to large-scale production, across various modalities including monoclonal antibodies, cell and gene therapies, and innovative biologics.

Key Products and Services:

• Development services (late discovery, cell line, process development, analytical)
• CGMP manufacturing for clinical and commercial biologics
• Antibody-drug conjugates (ADC) and mRNA manufacturing
• Quality assurance and control services
• Tech transfer and process optimisation services

Samsung Biologics continues to lead the industry in providing flexible and scalable solutions to biopharma clients worldwide, empowering them to bring life-changing medicines to market faster and more efficiently. With ongoing investments in infrastructure and cutting-edge technologies, the company is poised to maintain its position at the forefront of the global biologics manufacturing landscape.